ABSTRACT: Introduction: Paramyotonia congenita (PMC) is a nondystrophic myotonic disorder that is believed to be caused by a defect in Na v 1.4 sodium channel inactivation. Ranolazine, which acts by enhancing slow inactivation of sodium channels, has been proposed as a therapeutic option, but in vivo studies are lacking. Methods:
Paramyotonia congenita (PMC) is a rare autosomaldominant, nondystrophic myotonic disorder characterized by clinical myotonia and symptoms of muscle stiffness, pain, and a feeling of fatigue or weakness. Paramyotonia congenita results from missense mutations in SCN4A that lead to a gain-of-function in skeletal muscle Na v 1.4 sodium channels, usually caused by a defect of channel inactivation. 1, 2 Several sodium channel blockers have been clinically tested in myotonic disorders; however, only mexiletine and lamotrigine have been shown to reduce myotonia effectively in randomized, placebocontrolled trials. 3, 4 There are currently no US Food and Drug Administration-approved treatments for myotonia, and some patients either do not tolerate or show poor response to treatments such as mexiletine. 5 Recently, ranolazine (Ranexa; Gilead Sciences, Foster City, California), which was approved in 2006 for the indication of chronic angina, has been proposed as a possible therapeutic option because of its mechanism of enhancing slow inactivation of sodium channels. 6 One study of PMC mutants in vitro showed ranolazine to be effective in stabilizing the inactivated state in both mutant and wild-type sodium channels. 7 Because of its potential benefit and favorable safety profile, we conducted an openlabel, single-center trial of ranolazine in patients with PMC.
MATERIALS AND METHODS
Standard Protocol Approvals, Registrations, and Patient Consents. This study was approved by the institutional review board at The Ohio State University Wexner Medical Center and registered at www.clinicaltrials.gov (NCT02251457). Written informed consent was obtained from each participant.
Study Design. This single-center, open-label trial evaluated the efficacy and tolerability of ranolazine in participants with PMC. Participants were 18 years or older, had a diagnosis of PMC established by genetic testing of the participant or a first-degree relative, and had clinically evident myotonia. Those taking mexiletine, lacosamide, acetazolamide, phenytoin, quinine, procainamide, Saint John's wort, or tocainide were allowed to participate only after discontinuing the medication for a time period of 7 half-lives. Individuals taking CYP3A inducers or potent inhibitors, simvastatin exceeding 20 mg daily, metformin exceeding 1,700 mg daily, Pglycoprotein inhibitors or substrates, or QTc-prolonging drugs were excluded. Other exclusion criteria included hypersensitivity to the study drug, hepatic cirrhosis, creatinine clearance <30 ml/min, prolonged QTc (>470 ms for men and > 480 ms for women), pregnancy, history of malignancy or adenomatous polyps, or direct family history of sudden cardiac death.
Lamotrigine was not an exclusion criterion, but no participant took lamotrigine during the study period.
All participants were assessed at baseline and at weeks 2, 4, and 5. After the baseline assessment, patients received a 500-mg dose of ranolazine twice daily and continued until week 4 (patients did not receive any antimyotonia treatments at baseline and week 5). The dose was increased to 1,000 mg twice daily, as tolerated after the week-2 visit. During each assessment, a 12-lead electrocardiogram (EKG) was performed.
At each time point, participants rated severity of stiffness, weakness, and pain symptoms on a 0-9 scale, with 9 being the most severe. 3 Eyelid and handgrip myotonia were assessed by having participants squeeze their eyes shut or make a tight fist for 5 s and then rapidly opening. Five consecutive trials of each maneuver were performed, and time to full opening was measured. One trial of timed-up-and-go (TUG) was performed at each visit. 8 At baseline and at week 4, myotonia according to electromyography (EMG) was measured in the tibialis anterior (TA) and abductor digiti minimi (ADM) muscles, and the short exercise test (SET) of the ADM was performed as previously described. 9, 10 The presence or absence of myotonia after 15 needle movements (EMG frequency) and the duration of the longest sustained myotonic discharge (EMG duration) were assessed in the TA and ADM. Maximum ADM compound muscle action potential decrement was assessed during 3 trials of the SET. All assessments were performed blinded to results from prior assessments. Drug compliance was quantitated by using a drug diary and pill counts.
Statistical Analysis. The primary objective of this study was to compare outcomes at week 4 to those at baseline. Linear mixed-effects models included an indicator of visit and a random intercept for each participant. Electromyography duration, TUG, eyelid opening, and hand opening were log transformed to better satisfy model assumptions. The sign test was used to compare EMG frequencies at week 4 to baseline.
To control the familywise error rate at 0.1, we used the Bonferroni correction and thus conducted each test comparing outcomes at week 4 to baseline at the 0.01 level. We secondarily explored longitudinal changes for outcomes measured at multiple time points and compared EKG QTc and SET decrement by using a paired t test. From our prior study in FIG. 1a) . This improvement was also significant by week 2. After ranolazine was stopped at week 5, there was no longer a significant difference in symptoms compared with baseline in any variable.
Clinical Myotonia. Clinical myotonia improved after treatment with ranolazine. Timed-up-and-go, eyelid opening, and hand opening times all improved significantly at week 4 compared with those at baseline ( Table 1, FIG. 1b) . This improvement was also significant by week 2 in all 3 clinical measures. At week 5, there was no longer a significant difference compared with baseline.
Myotonia According to EMG and SET. Participants also showed improvement in myotonia according to EMG after treatment with ranolazine (Table 1, FIG. 1c) . Duration of TA myotonia according to EMG was significantly reduced at week 4 compared with that at baseline. Duration of ADM myotonia according to EMG showed a 60% reduction at week 4, but this was not significant. The change in TA and ADM myotonia according to EMG grades at week 4 was not significant. Maximum SET amplitude decrement was similar at week 4 (94.4% AE 11.2%) and at baseline (89.6% AE 11.2%; P = 0.113).
DISCUSSION
Our results showed that ranolazine was well tolerated and led to improvement in clinical myotonia and, to a lesser extent, in myotonia according to EMG in patients with PMC. These findings are in line with preclinical data and support the use of ranolazine as a treatment for myotonia. The results of this study are similar to our previous findings showing the effect of ranolazine in patients with MC. 10 Both PMC and MC patients showed a greater reduction in duration of myotonia according to EMG than in frequency of myotonia according to EMG. We suggest that this finding is a result of ranolazine's use-dependent block of sodium current, causing a reduction in the duration of myotonia without eliminating the initiation of myotonia. 10 In the current study, patients showed significant improvement in all subjective measures (i.e., stiffness, weakness, and pain). This is in contrast to patients with MC, who showed a statistically significant improvement only in subjective stiffness. 10 It has been proposed that mutations in SCN4A cause an increase in sodium persistent inward current, resulting in muscle depolarization and weakness in individuals with PMC. 7, 10, 11 Treatment with ranolazine has been shown to decrease the amplitude of the inward sodium current in PMC, suggesting that ranolazine directly targets the pathologic current responsible for both weakness and muscle stiffness.
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Although sodium persistent inward current does play a central role in triggering muscle stiffness in MC, the primary defect is a reduction in chloride current, [12] [13] [14] which is not reversed by treatment with ranolazine. The mechanism of action of ranolazine is more closely linked to the underlying defect in PMC, which may explain its greater efficacy in PMC compared with MC.
This study had several limitations; it was unblinded, not placebo controlled, performed at a single center, and made no comparison to an alternate treatment such as lamotrigine or mexiletine. Because the results show clinical benefit with ranolazine, a larger, randomized, placebo-controlled trial is warranted. In addition, comparison of different potential therapeutics in differing phenotypes and mutations may be required because genotype and phenotype could drive therapeutic effects.
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